论文部分内容阅读
目的:探讨HPV-DNA亚型检测联合液基细胞学对宫颈癌筛查的临床价值。方法:对自愿接受宫颈癌筛查的女性1462例作为研究对象,分别对其进行HPV-DNA亚型检测以及液基细胞学的检查,对于出现阳性的患者进行病理组织学检查。结果:HPV+TCT对宫颈癌早期病变以及癌变的检出率为69.67%明显高于HPV检查的56.28%以及TCT检查的63.89%(P<0.05);HPV+TCT对CINⅠ、CINⅡ、CINⅢ、癌的检出率分别为91.67%,92.86%、91.67%以及100%。结论:采用HPV-DNA亚型检测联合液基细胞学对宫颈癌筛查,可明显提高其对癌前病变的检出率,是一种高效、简单的检测方法。
Objective: To investigate the clinical value of HPV-DNA subtype detection combined with liquid-based cytology in cervical cancer screening. Methods: A total of 1462 women who were screened for cervical cancer voluntarily were enrolled in this study. HPV-DNA subtypes and liquid-based cytology were examined respectively. The positive patients were examined by histopathology. Results: The positive rate of HPV + TCT in early stage of cervical cancer and carcinogenesis was 69.67%, which was significantly higher than that of HPV (56.28%) and TCT (63.89%, P <0.05). HPV + TCT had no significant effect on CINⅠ, CINⅡ, CINⅢ, The detection rates were 91.67%, 92.86%, 91.67% and 100% respectively. Conclusion: HPV-DNA subtype detection combined with liquid-based cytology for cervical cancer screening can significantly increase the detection rate of precancerous lesions, is an efficient and simple detection method.